Observational studyFamilial cancer2014
Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families.
Observational study in Familial cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 91 citations in OpenAlex.
- The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators.European radiology · 2016Trial
- Automated Field of View Prescription for Whole-body Magnetic Resonance Imaging Using Deep Learning Based Body Region Segmentations.Investigative radiology · 2025Article
- Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.Nature reviews. Endocrinology · 2024Review
- An Update on Temporal Bone Paragangliomas.Current treatment options in oncology · 2023Review
- Radiomics in gastrointestinal stromal tumours: an up-to-date review.Japanese journal of radiology · 2023Review
- A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant.Familial cancer · 2023Article
- [Pheochromocytoma and paraganglioma during childhood and adolescence].Radiologie (Heidelberg, Germany) · 2022Review
- Tumour detection and outcomes of surveillance screening in SDHB and SDHD pathogenic variant carriers.Endocrine connections · 2022Article
- Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use.La Radiologia medica · 2021Review
- Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.Nature reviews. Endocrinology · 2021Review
- Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family.Journal of clinical medicine · 2020Article
- Imaging surveillance for children with predisposition to renal tumors.Pediatric radiology · 2019Review
- Whole-body magnetic resonance imaging of pediatric cancer predisposition syndromes: special considerations, challenges and perspective.Pediatric radiology · 2019Review
- Whole Body MRI and oncology: recent major advances.The British journal of radiology · 2018Review
- Imaging of cancer predisposition syndromes.Pediatric radiology · 2018Review
- Approach to wild-type gastrointestinal stromal tumors.Translational gastroenterology and hepatology · 2018Review
- New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.Endocrine reviews · 2017Review
- Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.JAMA oncology · 2017Article
- Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).Endocrine pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Patients with germline mutations in one of the SDH genes are at substantially increased risk of developing paragangliomas, pheochromocytomas (pheos), and other tumors (all combined referred to as SDH-related tumors). However, limited data exist on screening in SDH mutation carriers and no studies have evaluated whole-body MRI as a screening tool in asymptomatic patients. This was a single-center observational study. We evaluated the results of screening in 37 SDH carriers who underwent 45 whole-body MRIs and 47 biochemical tests. Screening included annual biochemical testing (catecholamines, metanephrines and chromogranin A) and biennial or annual rapid sequence whole-body MRI from the base of the skull to the pelvis beginning at age 10 years old. Six tumors (paragangliomas of the organ of Zuckerkandl, the aortocaval/vas deferens, of the carotid body times three, and a renal cell carcinoma) were diagnosed in five patients. In total, 13.5 % of all patients screened were diagnosed with SDH-related tumors. Whole-body MRI missed one tumor, while biochemical testing was normal in five patients with SDH-related tumors. The sensitivity of whole-body MRI was 87.5 % and the specificity was 94.7 %, while the sensitivity of biochemical testing was 37.5 % and the specificity was 94.9 %. Whole-body MRI had a higher sensitivity for SDH-related tumors than biochemical testing in patients undergoing screening due to their SDHB or SDHC mutation status. Whole-body MRI reduces radiation exposure compared to computed tomography scan and time compared to dedicated MRI of the head/neck, thorax, and abdomen/pelvis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.